相关实验视频

Updated: Jul 9, 2025

A Multimodal Imaging- and Stimulation-based Method of Evaluating Connectivity-related Brain Excitability in Patients with Epilepsy

A Multimodal Imaging- and Stimulation-based Method of Evaluating Connectivity-related Brain Excitability in Patients with Epilepsy

Published on: November 13, 2016

结构连接性作为预测因子,对治疗的 levetiracetam 的反应

Dong Ah Lee¹, Ho-Joon Lee², Kang Min Park³

¹Department of Neurology, Haeundae Paik Hospital, Inje University College of Medicine, Haeundae-ro 875, Haeundae-gu, Busan, 48108, Korea.

|November 28, 2023

概括

结构连接,而不是淋巴功能,预测了新病例中 levetiracetam (LEV) 的反应. 响应较差的人群中较高的网络复杂性表明,改变的大脑网络会影响LEV的有效性.

科学领域:

神经科学是一个神经科学.
医疗成像医学成像
发病学 (Epileptology) 是一个专业的学科.

背景情况:

的诊断和治疗需要有效预测药物反应.
列维 (LEV) 是一种常见的第一线抗药物.
识别LEV反应的生物标志物可以优化治疗策略.

研究的目的:

为了确定结构性大脑连接或淋巴系统功能是否预测新诊断的患者的 levetiracetam (LEV) 反应.
为了评估扩散张力成像 (DTI) 的实用性,我们推出了用于预测LEV治疗结果的指标.

主要方法:

八十四名新诊断的患者接受LEV单疗法被纳入.
通过对DTI扫描的图形理论分析来评估结构连接性.
用DTI扫描的DTI-ALPS指数来评估淋巴系统功能.

主要成果:

在良好的和差的LEV响应者之间,临床因素或DTI-ALPS指数没有显著差异.
较差的响应者显示出明显更高的平均聚类系数,全球效率和小世界性指数.
在ROC分析中,平均聚类系数是LEV反应的最强预测指标 (AUC=0.677),在后勤回归和生存分析中具有重要意义.

结论:

结构性大脑连接,特别是像平均聚类系数这样的网络测量,是新诊断的中 levetiracetam 反应的重要预测因子.
淋巴系统功能 (DTI-ALPS) 在这个队列中没有预测LEV反应.
这些发现突显了先进的神经成像技术在个性化治疗中的潜力.

关键词:

抗发作药物抗发作药物扩散张力成像的成像方法是一种病.莱维泰拉塞坦 (Levethiracetam) 是一种结构性的连接性结构性的连接性

更多相关视频

Statistical Modelling of Cortical Connectivity Using Non-invasive Electroencephalograms

Statistical Modelling of Cortical Connectivity Using Non-invasive Electroencephalograms

Published on: November 1, 2019

Network Analysis of the Default Mode Network Using Functional Connectivity MRI in Temporal Lobe Epilepsy

Network Analysis of the Default Mode Network Using Functional Connectivity MRI in Temporal Lobe Epilepsy

Published on: August 5, 2014

相关概念视频

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Arteries of the Lower Limbs

Arteries of the Lower Limbs

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...

Electroconvulsive Therapy

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Antiepileptic Drugs: Glutamate Antagonists

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...